Increased expression of SPRY4-IT1 predicts poor prognosis and promotes tumor growth and metastasis in bladder cancer

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 2, 2015, Pages 1954-1960

  Zhao, Xiao Lei ^a   Zhao, Zhen Hua ^a   Xu, Wen Chao ^a   Hou, Jun Qing ^a   Du, Xin Yi ^a  

^a HENAN UNIVERSITY   (China)

Author keywords

Invasion; Migration; Proliferation; SPRY4 IT1; Urothelial carcinoma of the bladder

Indexed keywords

LONG UNTRANSLATED RNA; NERVE PROTEIN; SIGNAL PEPTIDE; SPRY4 PROTEIN, HUMAN; TUMOR MARKER;

BLADDER TUMOR; CELL MOTION; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE; TUMOR INVASION; UPREGULATION;

BIOMARKERS, TUMOR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NERVE TISSUE PROTEINS; PROGNOSIS; RNA, LONG NONCODING; UP-REGULATION; URINARY BLADDER NEOPLASMS;

EID: 84928139484     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, Kiemeney L, Kriegmair M, Montironi R, Murphy WM, Sesterhenn IA, Tachibana M and Weider J. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005; 66: 4-34.
3. Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A and Witjes JA. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011; 59: 1009-1018.
4. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D and Skinner DG. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 666-675.
5. Prensner JR and Chinnaiyan AM. The emergence of lncRNAs in cancer biology. Cancer Discov 2011; 1: 391-407.
6. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011; 12: 861-874.
7. Costa FF. Non-coding RNAs: Meet thy masters. Bioessays 2010; 32: 599-608.
8. Wang KC and Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell 2011; 43: 904-914.
9. Geng YJ, Xie SL, Li Q, Ma J and Wang GY. Large intervening non-coding RNA HOTAIR is associated with hepatocellular carcinoma progression. J Int Med Res 2011; 39: 2119-2128.
10. Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, Zornig M, MacLeod AR, Spector DL and Diederichs S. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res 2013; 73: 1180-1189.
11. Han Y, Liu Y, Gui Y and Cai Z. Long intergenic non-coding RNA TUG1 is overexpressed in urothelial carcinoma of the bladder. J Surg Oncol 2013; 107: 555-559.
12. Khaitan D, Dinger ME, Mazar J, Crawford J, Smith MA, Mattick JS and Perera RJ. The melanomaupregulated long noncoding RNA SPRY4-IT1-modulates apoptosis and invasion. Cancer Res 2011; 71: 3852-3862.
13. Zhang HM, Yang FQ, Yan Y, Che JP and Zheng JH. High expression of long non-coding RNA SPRY4-IT1 predicts poor prognosis of clear cell renal cell carcinoma. Int J Clin Exp Pathol 2014; 7: 5801-5809.
14. Xie HW, Wu QQ, Zhu B, Chen FJ, Ji L, Li SQ, Wang CM, Tong YS, Tuo L, Wu M, Liu ZH, Lv J, Shi WH, Cao XF. Long noncoding RNA SPRY4-IT1 is upregulated in esophageal squamous cell carcinoma and associated with poor prognosis. Tumor Biol 2014; 35: 7743-54.
15. Zou Y, Jiang Z, Yu X, Sun M, Zhang Y, Zuo Q, Zhou J, Yang N, Han P, Ge Z, De W and Sun L. Upregulation of long noncoding RNA SPRY4-IT1 modulates proliferation, migration, apoptosis, and network formation in trophoblast cells HTR-8SV/neo. PLoS One 2013; 8: e79598.
16. Yang FQ, Huang JH, Liu M, Yang FP, Li W, Wang GC, Che JP and Zheng JH. Argonaute 2 is up-regulated in tissues of urothelial carcinoma of bladder. Int J Clin Exp Pathol 2014; 7: 340.
17. Bolenz C and Lotan Y. Molecular biomarkers for urothelial carcinoma of the bladder: challenges in clinical use. Nat Clin Pract Urol 2008; 5: 676-685.
18. Ponting CP, Oliver PL and Reik W. Evolution and functions of long noncoding RNAs. Cell 2009; 136: 629-641.
19. Mourtada-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F and Williams GT. GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene 2009; 28: 195-208.
20. Sun M, Xia R, Jin F, Xu T, Liu Z, De W and Liu X. Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer. Tumour Biol 2014; 35: 1065-1073.
21. Ma MZ, Kong X, Weng MZ, Zhang MD, Qin YY, Gong W, Zhang WJ and Quan ZW. Long noncoding RNALET is a positive prognostic factor and exhibits-tumorsuppressive activity in gallbladder cancer. Mol Carcinog 2014; [Epub ahead of print].